Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.